Section Arrow
Quote
MNPR.NASDAQ
- Monopar Therapeutics Inc
Quotes are at least 15-min delayed:2025/07/21 19:23 EDT
After Hours
Last
 45.53
-0.9 (-1.94%)
Bid
45.53
Ask
46.25
High 46.43 
Low 45.53 
Volume 1227 
Regular Hours
Last
 46.43
-0.05 (-0.11%)
Day High 
48.3504 
Prev. Close
46.48 
1-M High
50.14 
Volume 
30.28K 
Bid
45.53
Ask
46.25
Day Low
45.11 
Open
47.1 
1-M Low
31.17 
Market Cap 
284.24M 
Currency USD 
P/E -- 
%Yield -- 
10-SMA 40.94 
20-SMA 37.44 
50-SMA 36.19 
52-W High 54.3 
52-W Low 1.719 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-3.98/-1.68
Enterprise Value
284.24M
Balance Sheet
Book Value Per Share
8.76
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
--
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
TNFATNF Pharmaceuticals Inc.0.1294+0.0419+47.89%-- 
After Hours 0.1192 -0.0102 -7.88%
NCNANuCana plc0.051+0.0033+6.92%-- 
After Hours 0.057 +0.006 +11.76%
PMNProMIS Neurosciences1.12+0.6799+154.49%5PE
After Hours 1.07 -0.05 -4.46%
SABSSAB Biotherapeutics2.7+0.13+5.06%-- 
After Hours 2.6696 -0.0304 -1.13%
RXRXRecursion Pharmaceuticals6.4+0.56+9.59%-- 
After Hours 6.45 +0.05 +0.78%
Quotes are at least 15-min delayed：2025/07/21 19:23 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. The company's pipeline consists of Validive for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients, camsirubicinfor the treatmentof soft tissue sarcoma, a late-stage preclinical antibody, MNPR-101, for cancers and severe COVID-19 and an early-stage camsirubicin analog, MNPR-202, for various cancers.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.